PBI 4050

Drug Profile

PBI 4050

Alternative Names: PBI4050

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator ProMetic Life Sciences
  • Class Anti-inflammatories; Antifibrotics; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; Extracellular matrix protein modulators; Immunomodulators; Inflammation mediator inhibitors; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn genetic disorders; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Inborn genetic disorders; Metabolic syndrome; Scleroderma; Type 2 diabetes mellitus
  • Preclinical Acute lung injury; Pulmonary arterial hypertension; Renal fibrosis
  • No development reported Anaemia; Haematological disorders; Neutropenia

Most Recent Events

  • 21 Jun 2017 Phase-II clinical trials in Scleroderma in Canada (PO) before June 2017 (ProMetic Life Sciences pipeline, June 2017)
  • 14 Jun 2017 ProMetic BioSciences plans a phase II/III trial for Alstrom's syndrome in United Kingdom (NCT03184584)
  • 29 May 2017 ProMetic BioSciences initiates a phase II trial for Metabolic syndrome in patients with Type-2 diabetes mellitus in Canada (NCT03081598)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top